A recent analysis reveals that while 197 new cancer drugs were launched from 2018 to 2022, high-income countries benefit significantly more than lower-income regions, which face delays or lack access to these treatments. The study highlights disparities in drug availability, with the US leading in new drug launches. It suggests that as life expectancy increases in low-income countries, cancer incidence may rise, exacerbating healthcare challenges. Experts call for tiered pricing and improved healthcare systems to address these inequalities. Teljes cikk (Euronews.com)